Biotech billionaire gains $250M investment for big data play; Struggling Ariad wins a BTD for lung cancer drug;

@FierceBiotech: Intarcia's annual diabetes treatment aces two Phase III trials. More | Follow @FierceBiotech

@JohnCFierce: Imagine that, $LLY's tabalumab fails for lupus, just like it failed for RA. Release | Follow @JohnCFierce

@DamianFierce: Calithera pulls off an $80M IPO. Release | Follow @DamianFierce

@EmilyMFierce: NIH grants up to $70M to develop new vaccine adjuvants. More from FierceVaccines | Follow @EmilyMFierce

> Biotech billionaire Patrick Soong-Shiong has added a whopping $250 million investment from Kuwait's sovereign wealth fund for NantHealth, which plans to use big data to help transform the way that healthcare is delivered to patients. The company is also adding several execs, including Steve Curd as the new COO. "Our new leadership team has the expertise, relationships and deep knowledge necessary to drive NantHealth forward and make our vision of transforming the healthcare system and delivering truly personalized medicine a reality," said Soon-Shiong in a statement. This new investment brings the company's B round to $320 million. Release

> Shares of the struggling Ariad ($ARIA) got a boost this morning after the Cambridge, MA-based biotech reported that its drug AP26113 won breakthrough drug status at the FDA for ALK-positive non-small cell lung cancer. Shares jumped 9%. Release

> Incyte ($INCY) has scored a $60 million milestone from Novartis ($NVS) related to the reimbursement for Jakavi in Europe. Release

Medical Device News

@FierceMedDev: We've compiled the 15 fiercest med tech companies. Check out FierceMedicalDevices' Fierce 15. Special Report | Follow @FierceMedDev

@MichaelGFierce: RT @EmilyMFierce: Did you miss our list of notable academic-pharma alliances of 2014? Check it out here. Report from FierceBiotechResearch | Follow @MichaelGFierce

@VarunSaxena2: FDA finalizes cybersecurity guidance in push to secure devices from hackers. Story | Follow @VarunSaxena2

@EmilyWFierce: Gene in monarchs could explain why migratory butterflies are marathoners, rather than sprinters. More from the NYT | Follow @EmilyWFierce

> Boehringer pilots inhalers with sensors to encourage patient adherence. Story

> Philips slapped with $466M verdict in Masimo patent battle. News

Pharma News

@FiercePharma: Our newest special report is live! Check out The top 10 pharma companies by employees. Feature | Follow @FiercePharma

@CarlyHFierce: RT @FiercePharma: Top-read special report Wednesday: The top 10 pharma companies by 2013 revenue. Report | Follow @CarlyHFierce

> What's #trending in pharma on social media? Investors are listening to find out. Article

> Zogenix races to FDA with abuse-deterrent version of maligned pain pill Zohydro. Report

Vaccines News

> Sanofi to roll out quadrivalent flu jab in Canada amid GSK manufacturing woes. Report

> NIH grants up to $70M to develop vaccine adjuvants. More

> WHO: NGO mix-up caused Syrian measles vaccine deaths. Item

> Immunotherapy combos could provide a new path forward for troubled cancer vaccine field. Story

> Merck Gardasil follow-up could block 90% of cervical cancers--if uptake improves, that is. Article

Pharma Manufacturing News

> Health Canada places import ban on Apotex and IPCA Laboratories. More

> Boehringer to invest a further $19M in German plant expansion. Item

> India sending inspectors on facility visits with global peers. Story

> Officials search for ways to boost output of plant-made Ebola drugs. Article

> PhRMA dealt another legal blow in fight against drug disposal law. Report

Suggested Articles

The FDA sent Eton's partner, Bausch Health, a complete response letter that raised “no concerns” about the clinical data in the drug’s application.

A new partnership will test drug cocktails containing Karyopharm's new product Xpovio in cell samples from glioblastoma patients.

Boehringer signed a deal to buy out a small immuno-oncology player this morning, and AbbVie’s been at it, too, inking a deal to snap up Mavupharma.